Although both GLP-1RAs and DPP4is target the incretin pathway, GLP-1RAs demonstrate greater reductions in hemoglobin A1c levels and body weight, improved β-cell and cardiac function, and lower albuminuria.6 These effects may reduce cancer progression by mitigating hyperinsulinemia and inflammation, while also lowering overall mortality through broader health improvements. This evidence concerns the gene GCG and hyperinsulinism.